Status:
COMPLETED
Study of the Safety, Tolerability, Pharmacokinetics and Pharmcodynamics of ILV-094 in Healthy Subjects
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Healthy
Eligibility:
All Genders
18-50 years
Phase:
PHASE1
Brief Summary
This a randomized, double-blind placebo-controlled inpatient/outpatient, sequential group study of ascending single IV doses of ILV-094, an investigational drug, administered to healthy subjects. In a...
Eligibility Criteria
Inclusion
- Healthy subjects (Men or women of nonchildbearing potential ), aged 18 to 50 years.
- Body mass index in the range of 18 to 30 Kg/m2 and body weight greater than 50 Kg.
- Healthy as determined by the investigator on the basis of medical history, physical examination, clinical laboratory test results, vital signs, and 12-lead electrocardiogram.
Exclusion
Key Trial Info
Start Date :
December 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2007
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT00447681
Start Date
December 1 2006
End Date
November 1 2007
Last Update
December 13 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Philadelphia, Pennsylvania, United States, 19148